Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

d special and acquisition-related charges

(f) Included in cumulative effect in change in accounting principle, net

SCHERING-PLOUGH CORPORATION

Report for the period ended December 31 (unaudited):

GAAP Net Sales by Key Product

(Dollars in millions) Fourth Quarter Full Year

2007 2006 % 2007 2006 %

GLOBAL

PHARMACEUTICALS a/ $2,963 $2,211 34% $10,173 $8,561 19%

REMICADE 455 337 35% 1,648 1,240 33%

NASONEX 271 253 7% 1,092 944 16%

PEGINTRON 239 208 15% 911 837 9%

TEMODAR 234 189 23% 861 703 22%

CLARINEX /

AERIUS 174 164 6% 799 722 11%

CLARITIN RX 93 78 19% 391 356 10%

AVELOX 115 103 12% 384 304 26%

INTEGRILIN 91 85 7% 332 329 1%

REBETOL 71 75 (6%) 277 311 (11%)

CAELYX 66 49 33% 257 206 25%

INTRON A 57 57 - 233 237 (2%)

SUBUTEX /

SUBOXONE 57 51 11% 220 203 8%

PROVENTIL /

ALBUTEROL CFC 41 55 (25%) 207 203 2%

ASMANEX 41 36 16% 162 103 57%

ELOCON 37 33 10% 156 141 11%

FORADIL 25 28 (11%) 102 94 8%

NOXAFIL 29 10 N/M 89 19 N/M

FOLLISTIM c/ 57 - N/M 57 - N/M

NUVARING c/ 45 - N/M 45 - N/M

<
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... native amino acid sequence , , ... Barbara McGowan * Joseph,A. Sorge * Peter Vaillancourt ... the Affinity protein expression and,purification system by the ... and expression vector is designed for consistent, high-level ...
... integrated DNA-removal step , Karen Dolter Jeff ... miniprep kit efficiently,isolates high-quality total RNA from 10 ... 10 to 40 mg of tissue and includes an ... because of the,easy-to-follow technique. The RNA isolation is performed ...
... Long DNA polymerase to genotype,mice , Evgeny Loukianov ... University of Cincinnati, Cincinnati, OH , We developed a ... genomic DNA is isolated from mouse ear clips, and,large ... DNA,polymerase.* , , PCR is the method of ...
Cached Biology Technology:Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 2Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 3Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 4Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 5Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 6Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 7Expression and Purification of Recombinant Proteins That Have Native Amino,Acid Sequence 8Simple Isolation of RNA from Tissue and Cultured Cells 2Simple Isolation of RNA from Tissue and Cultured Cells 3Simple Isolation of RNA from Tissue and Cultured Cells 4Simple Isolation of RNA from Tissue and Cultured Cells 5Simple Isolation of RNA from Tissue and Cultured Cells 6Simple Isolation of RNA from Tissue and Cultured Cells 7Simple Isolation of RNA from Tissue and Cultured Cells 8Easily Amplify Genomic DNA with Long-Distance PCR 2Easily Amplify Genomic DNA with Long-Distance PCR 3Easily Amplify Genomic DNA with Long-Distance PCR 4Easily Amplify Genomic DNA with Long-Distance PCR 5Easily Amplify Genomic DNA with Long-Distance PCR 6Easily Amplify Genomic DNA with Long-Distance PCR 7
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... remarkable eyes of a marine crustacean could inspire the next ... study from the University of Bristol published today in ... are found on the Great Barrier Reef in Australia and ... They can see in twelve colours (humans see in only ...
... 23 GenVault Corporation, the leader in ambient temperature ... announced that David Wellis, Ph.D., GenVault,s President and CEO, ... place on October 26th and 27th in La Jolla, ... an overview of the company together with recent customer, ...
... A bioethicist who specializes in moral dilemmas families face ... the first-ever March of Dimes Distinguished Lectureship in Perinatal Bioethics. ... John D. Lantos, MD, a nationally-recognized pediatrician and ethicist, delivered ... at the American Society of Bioethics and Humanities, 11th annual ...
Cached Biology News:Mantis shrimps could show us the way to a better DVD 2GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2March of Dimes establishes 2 new perinatal bioethics awards 2
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
FITC~Bovine Serum Albumin...
Biology Products: